Therapeutic Efficacy of Mirogabalin in managing Trigeminal Neuralgia

• Souichirou Tadokoro ^[1] ; Naoki Otani ^[1] ; Andrew Young ^[2] ; Kana Ozasa ^[1] ; Noboru Noma ^[1]
  1. [1] Nihon University

     Nihon University

     Japón

     
  2. [2] MSD, DDS, Department of Diagnostic Sciences, Arthur Dugoni School of Dentistry, University of the Pacific, San Francisco, United States
• Localización: Journal of Clinical and Experimental Dentistry, ISSN-e 1989-5488, Vol. 16, Nº. 5 (May), 2024, págs. 652-655
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Trigeminal neuralgia presents significant challenges in management, often requiring alternative pharmacotherapy due to resistance or side effects to first-line medications like carbamazepine. This case series investigates the efficacy and safety of mirogabalin, a novel α2δ ligand, in six trigeminal neuralgia patients. Mirogabalin demonstrated varying degrees of pain reduction, with an average Numerical Rating Scale improvement rate of 43.1%. Side effects were generally mild, with drowsiness and dizziness being the most common. Despite limited efficacy in some cases, mirogabalin shows promise as a potential treatment option for trigeminal neuralgia, warranting further investigation.